Subscribe
istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
15 May 2018Americas

Eli Lilly to acquire cancer drug developer

Eli Lilly has revealed plans to acquire Montreal-based AurKa Pharma, in what is the company’s second acquisition in less than one week.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.


Editor's picks

Bankruptcy judge approves $305m sale of genetics testing company
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

Editor's picks

Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025

More on this story

Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

More on this story

Americas
Eli Lilly to purchase Loxo Oncology for $8bn
7 January 2019   American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.
Big Pharma
AbbVie in immuno-oncology agreement with biotech
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Americas
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11 May 2018   Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

More features

Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations